Sun Pharmaceutical Industries Q2 Results FY27: PAT Falls 36.22% to Rs 1,988.53 Cr, Revenue Rs 16,198.71 Cr

Sun Pharmaceutical Industries Ltd (SUNPHARMA) Q2 Results FY27 announced on 30 October 2026, covering the company's financial performance for the July to September quarter. The results date brings Sun Pharmaceutical Industries Q2 Results FY27 into focus, with revenue of Rs 16,198.71 Cr, up 11.88% YoY, and PAT of Rs 1,988.53 Cr, down 36.22% YoY. Univest tracks both lines against the same quarter last year.

This results analysis of Sun Pharmaceutical Industries Q2 Results covers the financial highlights, the business drivers named in the disclosures, the outlook and the risks. The Financial Highlights table below sets the quarter against the same quarter last year before the discussion moves ahead.

Click Here – Get Free Investment Predictions

Sun Pharmaceutical Industries Q2 Results FY27: Financial Highlights

Metric	Q2 FY27 (Sep 26)	Q2 FY26 (Sep 25)	YoY Change
Revenue	Rs 16198.71 Cr	Rs 14478.31 Cr	+11.88% YoY
Net Profit (PAT)	Rs 1988.53 Cr	Rs 3117.95 Cr	-36.22% YoY

Source: company filing for Sun Pharmaceutical Industries Q2 Results FY27, 30 October 2026. Figures in Rs Crore.

Key Takeaways from Sun Pharmaceutical Industries Q2 Results: What Stands Out

• Revenue: Rs 16,198.71 Cr for the quarter, ahead of Rs 14,478.31 Cr in the corresponding quarter of last year, an increase of 11.88%.
• Net profit: Rs 1,988.53 Cr, compared with Rs 3,117.95 Cr a year earlier, a decline of 36.22% on a YoY basis.
• Margin: Net profit margin narrowed to 12.3% from 21.5% in the comparison quarter, even as revenue expanded.
• Balance sheet: The company is almost debt free, with a debt-to-assets ratio of 0.05 in FY26, per the disclosed figures.
• Next step: Sun Pharmaceutical Industries Q2 Results FY27 now move to the performance analysis, where YoY growth in revenue is weighed against the fall in profit.

Sun Pharmaceutical Industries Q2 Results FY27: Performance Analysis

YoY growth in revenue was 11.88% in the quarterly results, but net profit moved the other way. Revenue reached Rs 16,198.71 Cr against Rs 14,478.31 Cr, while net profit dropped to Rs 1,988.53 Cr from Rs 3,117.95 Cr, a fall of 36.22%.

In absolute terms, revenue added Rs 1,720.40 Cr over the year, whereas net profit lost Rs 1,129.42 Cr. Sun Pharmaceutical Industries Q2 Results FY27 therefore show a wider revenue base alongside a smaller profit line, a pairing that this results analysis treats as the central fact of the quarter.

Net profit also sits below the preceding quarter, which stood at Rs 2,894.79 Cr. Readers following Sun Pharmaceutical Industries Q2 Results on the Univest Screener can line these figures up against earlier filings, which is where the results analysis turns to the business factors.

Check the Univest Screener for live results data

Key Business Factors This Quarter

Revenue Growth – The results analysis points first to revenue, which grew 11.9% year on year to Rs 16,198.71 Cr in the latest quarter. This top line figure anchors the quarterly results and is the growth-side number for the period.

Return on Capital Employed – Return on capital employed was 19.11% in FY26, a reference point drawn from the last full financial year rather than from this quarter. It describes how the capital base was used before the quarter began.

Low Debt – The company is almost debt free, with a debt-to-assets ratio of 0.05 in FY26. In the context of Sun Pharmaceutical Industries Q2 Results FY27, borrowings form a very small part of the asset base, which carries the discussion into the FY27 outlook.

FY27 Outlook After Sun Pharmaceutical Industries Q2 Results

The FY27 outlook rests on the quarters still to be reported, because a single quarter does not settle a full year. Sun Pharmaceutical Industries Q2 Results FY27 give the second data point of the year, with revenue of Rs 16,198.71 Cr and net profit of Rs 1,988.53 Cr. Full-year FY27 results will depend on subsequent quarters and on disclosed sector conditions.

Net profit is the line to track most closely, since it fell 36.22% YoY while revenue grew 11.88%. This results analysis keeps every figure tied to the reported numbers, and the Univest app holds the quarterly figures in one place for comparison. The risks that follow are the ones tied directly to the profit line.

Key Risks to Watch After Sun Pharmaceutical Industries Q2 Results FY27

Net Profit Decline

Net profit fell 36.2% year on year to Rs 1,988.53 Cr, against Rs 3,117.95 Cr in the same quarter last year. This is the sharpest movement in Sun Pharmaceutical Industries Q2 Results FY27, so it is the first item to monitor.

Narrower Net Profit Margin

Net profit margin narrowed to 12.3% from 21.5% in the comparison quarter. Revenue showed YoY growth of 11.88%, yet a smaller share of each rupee of sales converted into net profit than a year earlier.

Sequential Profit Decline

Net profit was down 31.3% quarter on quarter from Rs 2,894.79 Cr. The sequential drop sits alongside the annual fall, so both comparisons point the same way for this quarter's profit line.

Download the Univest iOS App or Univest Android App to track quarterly results as they are declared.

Conclusion

Sun Pharmaceutical Industries Q2 Results FY27 show revenue growth of 11.88% YoY alongside a 36.22% fall in net profit, so the quarterly results carry two opposing signals. Later filings will show how the two lines settle over FY27. Anyone reading Sun Pharmaceutical Industries Q2 Results on Univest should consult a SEBI-registered advisor before acting.

Frequently Asked Questions on Sun Pharmaceutical Industries Q2 Results FY27

What are Sun Pharmaceutical Industries Q2 Results FY27?

Ans. Sun Pharmaceutical Industries Q2 Results FY27 cover the July to September 2026 quarter, with revenue of Rs 16,198.71 Cr and net profit of Rs 1,988.53 Cr. Alongside this, the full set of numbers sits in the Financial Highlights section above.

What is the results date for Sun Pharmaceutical Industries Q2 Results FY27?

Ans. Sun Pharmaceutical Industries declared its quarterly numbers on 30 October 2026 for the July to September 2026 period. This results date appears in the Quick Answer and the opening paragraph, so the timeline stays consistent through the article.

What revenue was reported in Sun Pharmaceutical Industries Q2 Results FY27?

Ans. Sun Pharmaceutical Industries reported revenue of Rs 16,198.71 Cr, compared with Rs 14,478.31 Cr a year ago, which means the top line rose 11.88%. The Performance Analysis section sets this against the profit line.

What net profit was reported in Sun Pharmaceutical Industries Q2 Results FY27?

Ans. Sun Pharmaceutical Industries reported net profit of Rs 1,988.53 Cr, compared with Rs 3,117.95 Cr in the same quarter last year, so net profit is lower by 36.22%. The Key Takeaways section lists this beside revenue.

How much YoY growth did revenue show in Sun Pharmaceutical Industries Q2 Results FY27?

Ans. Revenue showed YoY growth of 11.88% for Sun Pharmaceutical Industries, moving from Rs 14,478.31 Cr to Rs 16,198.71 Cr. Alongside this, the Performance Analysis section shows that the revenue gain of Rs 1,720.40 Cr came with lower net profit.

Did net profit rise or fall in Sun Pharmaceutical Industries Q2 Results?

Ans. Net profit fell for Sun Pharmaceutical Industries, declining 36.22% YoY to Rs 1,988.53 Cr from Rs 3,117.95 Cr. Compared with the preceding quarter at Rs 2,894.79 Cr, it is also lower, as the Key Risks section notes.

What was the net profit margin in Sun Pharmaceutical Industries Q2 Results FY27?

Ans. Net profit margin was 12.3% in Sun Pharmaceutical Industries Q2 Results FY27, narrower than 21.5% in the comparison quarter. This means a smaller share of each rupee of revenue reached net profit, as the Key Risks section explains.

How did net profit compare with the previous quarter in Sun Pharmaceutical Industries Q2 Results?

Ans. Net profit was down 31.3% quarter on quarter, from Rs 2,894.79 Cr to Rs 1,988.53 Cr. Alongside this, the YoY fall of 36.22% appears in the Financial Highlights table and the Key Takeaways list.

What business factors shaped Sun Pharmaceutical Industries Q2 Results FY27?

Ans. The disclosed factors include revenue growth of 11.9% year on year, return on capital employed of 19.11% in FY26 and a debt-to-assets ratio of 0.05, while the Key Business Factors section explains each one.

What are the key risks after Sun Pharmaceutical Industries Q2 Results FY27?

Ans. The key risks are a 36.2% year on year fall in net profit, a narrower margin of 12.3% and a 31.3% quarter on quarter decline. Alongside this, the Key Risks section gives each point with its figures.

What is the outlook after Sun Pharmaceutical Industries Q2 Results?

Ans. Full-year FY27 results will depend on the coming quarters and on disclosed sector conditions after the second quarter. Which means the FY27 Outlook section stays tied to the reported revenue and net profit figures.

Where can I find the complete Sun Pharmaceutical Industries Q2 Results FY27 data?

Ans. The complete data for Sun Pharmaceutical Industries Q2 Results FY27 sits in the Financial Highlights table in this article, covering revenue and net profit against the same quarter last year. The Univest Screener lets readers compare other listed names.